Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 12;13(9):e0203601.
doi: 10.1371/journal.pone.0203601. eCollection 2018.

The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort

Nikos Pantazis  1 , Maria Chini  2 , Anastasia Antoniadou  3 , Helen Sambatakou  4 , Athanasios Skoutelis  5 , Panagiotis Gargalianos  6 , Sophia Kourkounti  7 , Charalambos Gogos  8 , George Chrysos  9 , Mina Psichogiou  10 , Nikolaos V Sipsas  11 , Olga Katsarou  12 , Periklis Panagopoulos  13 , Simeon Metallidis  14 , Giota Touloumi  1 ; AMACS
Affiliations

The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort

Nikos Pantazis et al. PLoS One. .

Abstract

Combined Antiretroviral therapy (cART) has improved life-expectancy of people living with HIV (PLHIV) but as they age, prevalence of chronic non-AIDS related comorbidities may increase. We study the evolution of HIV-disease markers and comorbidities' prevalence in PLHIV in Greece. Two cross-sectional analyses (2003 and 2013) on data from the AMACS cohort were performed. Comparisons were based on population average models and were repeated for subjects under follow-up at both 2003 and 2013. 2,403 PLHIV were identified in 2003 and 4,910 in 2013 (1,730 contributing for both cross-sections). Individuals in 2013 were on average older, diagnosed/treated for HIV for longer, more likely to be on cART, virologically suppressed, and with higher CD4 counts. Chronic kidney disease, dyslipidemia and hypertension prevalence increased over time. There was an increase in prescription of lipid-lowering treatment (3.5% in 2003 vs. 7.7% 2013, p<0.001). Among 220 and 879 individuals eligible for Framingham 10-year Event Risk calculation, the proportion of patients in the high-risk group (>20%) increased from 18.2% to 22.2% (p = 0.002). Increase in the prevalence of comorbidities was more pronounced in the subset of patients who were followed in both 2003 and 2013. The increased availability and uptake of cART led to significant improvements in the immuno-virological status of PLHIV in Greece, but they aged alongside an increase in prevalence of non-AIDS related comorbidities. These results highlight the need for appropriate monitoring, optimal cART selection and long-term management and prevention strategies for such comorbidities.

PubMed Disclaimer

Conflict of interest statement

This study was supported by Gilead Sciences. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Flow chart for the selection of the 2003 and 2013 cross-sectional samples.
Fig 2
Fig 2
Distribution of age, antiretroviral treatment, HIV-RNA viral load and CD4 cell count in a) open cohort (all eligible patients) and b) closed cohort (subgroup of common patients in 2003 and 2013).
Fig 3
Fig 3
Prevalence of comorbidities, treatment (TRT) for hypertension (HTN) or lipid lowering, blood pressure, lipids and serum creatinine levels in a) open cohort (all eligible patients) and b) closed cohort (subgroup of common patients in 2003 and 2013).
Fig 4
Fig 4
Framingham risk score and estimated glomerular filtration rate (eGFR) quantitatively in categories in a) open cohort (all eligible patients) and b) closed cohort (subgroup of common patients in 2003 and 2013).
Fig 5
Fig 5
Prevalence of comorbidities in 2013 (black lines) and 2003 (grey lines) by age group in a) open cohort (all eligible patients) and b) closed cohort (subgroup of common patients in 2003 and 2013; results shown by their age in 2003). Six patients, aged 70+ in 2003, not shown in sub-figure b.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33. 10.1056/NEJM199709113371101 . - DOI - PubMed
    1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–9. . - PubMed
    1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60. 10.1056/NEJM199803263381301 . - DOI - PubMed
    1. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195–207. 10.1111/j.1468-1293.2012.01051.x . - DOI - PubMed
    1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685–92. 10.1097/QAD.0b013e32802ef30c . - DOI - PubMed

Publication types

Substances